SCHEMBL25569474

SCHEMBL25569474

CNC(CO)C(=O)c1ccc2c(c1)SCC2

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 3/20 0.32
MAPT P10636 3/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.32
HPGD P15428 1/20 0.32
CASP3 P42574 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HSD17B10 Q99714 2/20 0.32
NPC1 O15118 1/20 0.32
HTR1B P28222 2/20 0.32
ALOX15 P16050 1/20 0.30
CASP1 P29466 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25668178 0.90 HDAC1 (0.31) KDM4EALDH1A1MAPTLMNAHDAC1
SCHEMBL24197468 0.90 MAPT (0.34) KDM4EALDH1A1MAPTLMNAMEN1
SCHEMBL25569475 0.88 HDAC1 (0.32) KDM4EALDH1A1MAPTLMNAMEN1
SCHEMBL25569476 0.88 MAPT (0.32) KDM4EALDH1A1MAPTLMNAMEN1
SCHEMBL25569463 0.87 KDM4E (0.33) KDM4EALDH1A1MAPTLMNAHDAC1
SCHEMBL25668207 0.85 TAS1R3 (0.35) KDM4EALDH1A1MAPTLMNAMEN1
SCHEMBL25569487 0.84
SCHEMBL24197476 0.82 HTR1B (0.45) KDM4EALDH1A1MAPTLMNAMEN1
SCHEMBL24197470 0.81 MAPT (0.33) KDM4EALDH1A1MAPTLMNAMEN1
SCHEMBL25569478 0.79 HDAC1 (0.32) KDM4EALDH1A1MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT SLC6A3, CREBBP, SLC1A2 KDM4E 2362/4885ALDH1A1 2491/4885MAPT 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.